Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission

Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission
Results from an 8-week clinical trial coupled with an 8-week trial extension show evidence that children with refractory ulcerative colitis (UC) can achieve and maintain remission when treated with the small molecule drug thalidomide. The trial, a pilot effort from multiple medical centers in Italy, evaluated 26 children treated with either thalidomide or placebo. The researchers found that thalidomide-treated children maintained clinical remission for an average of 135 weeks, whereas placebo-treated children maintained clinical remission for only 8 weeks. "Twenty-six children with refractory UC were randomized to thalidomide or placebo," stated lead author Marzia Lazzerini, DTMH, MSc, PhD, in the study, "Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial," which was published in the journal Inflammatory Bowel Diseases. "Clinical remission at week eight was achieved by significantly more children treated with thalidomide." Twelve children were treated with thalidomide. Of these, ten achieved remission. Eleven were treated with placebo, and only two achieved remission. The trial was designed to open thalidomide treatment to patients on placebo after eight weeks. When the switch was made, eight of the eleven children achieved remission by the next set of eight weeks. Treatment consisted of a daily dose of thalidomide that was determined based on the patients' weights. All other drugs for managing the patients' UC were suspended to prevent confounding factors. Only children with severe UC or those who relapsed during steroid treatment were allowed to continue to take steroids. Thalidomide acts through suppressing tumor necrosis factor alpha, modulat
Subscribe or to access all post and page content.